Cytokinetics | CYTK - Operating Profit


Cytokinetics reported $-166.76M in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
Acadia Pharmaceuticals USD 35.76M 3.38M Sep/2025
Amgen USD 3.96B 464M Dec/2025
Bayer EUR -543M 556M Sep/2025
Biogen USD 659.6M 192.2M Sep/2025
Bristol-Myers Squibb USD 3.64B 135M Sep/2025
Cytokinetics USD -166.76M 55.25M Sep/2025
Eisai JPY 13.67B 7.07B Sep/2025
Eli Lilly USD 8.39B 1.37B Sep/2025
Exelixis USD 256.36M 42.78M Sep/2025
Geron USD -13.89M 1.43M Sep/2025
Halozyme Therapeutics USD 217.92M 15.48M Sep/2025
Ionis Pharmaceuticals USD -160.18M 300.02M Sep/2025
Ligand Pharmaceuticals USD 158.89M 149.17M Sep/2025
Merck USD 6.24B 318M Dec/2025
Novartis USD 4.5B 363M Sep/2025
Pfizer USD 4.65B 3.99B Dec/2025
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Roche Holding CHF 9.56B 3.8B Dec/2025
Sanofi EUR 1.7B 2.17B Dec/2025